Nature Communications (Sep 2022)
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
- Yoshihisa Kobayashi,
- Geoffrey R. Oxnard,
- Elizabeth F. Cohen,
- Navin R. Mahadevan,
- Joao V. Alessi,
- Yin P. Hung,
- Arrien A. Bertram,
- David E. Heppner,
- Mauricio F. Ribeiro,
- Karina P. Sacardo,
- Rodrigo Saddi,
- Mariana P. Macedo,
- Rafael B. Blasco,
- Jiaqi Li,
- Kari J. Kurppa,
- Tom Nguyen,
- Emma Voligny,
- Guruprasad Ananda,
- Roberto Chiarle,
- Artur Katz,
- Michael Y. Tolstorukov,
- Lynette M. Sholl,
- Pasi A. Jänne
Affiliations
- Yoshihisa Kobayashi
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School
- Geoffrey R. Oxnard
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
- Elizabeth F. Cohen
- Department of Informatics and Analytics, Dana-Farber Cancer Institute
- Navin R. Mahadevan
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School
- Joao V. Alessi
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
- Yin P. Hung
- Department of Pathology, Massachusetts General Hospital
- Arrien A. Bertram
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
- David E. Heppner
- Department of Chemistry, University at Buffalo, State University of New York
- Mauricio F. Ribeiro
- Department of Medical Oncology, Hospital Sírio-Libanês
- Karina P. Sacardo
- Department of Medical Oncology, Hospital Sírio-Libanês
- Rodrigo Saddi
- Department of Medical Oncology, Hospital Sírio-Libanês
- Mariana P. Macedo
- Department of Pathology, Hospital Sírio-Libanês
- Rafael B. Blasco
- Department of Pathology, Boston Children’s Hospital
- Jiaqi Li
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School
- Kari J. Kurppa
- Institute of Biomedicine, and MediCity Research Laboratories, University of Turku
- Tom Nguyen
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
- Emma Voligny
- Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute
- Guruprasad Ananda
- Department of Data Science, Dana-Farber Cancer Institute
- Roberto Chiarle
- Department of Pathology, Boston Children’s Hospital
- Artur Katz
- Department of Medical Oncology, Hospital Sírio-Libanês
- Michael Y. Tolstorukov
- Department of Informatics and Analytics, Dana-Farber Cancer Institute
- Lynette M. Sholl
- Department of Pathology, Brigham and Women’s Hospital
- Pasi A. Jänne
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School
- DOI
- https://doi.org/10.1038/s41467-022-33210-2
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 14
Abstract
Fusion genes have been proposed as a potential mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. Here, the authors identify gene fusions that are associated with resistance to EGFR TKIs in non-small cell lung cancers, and test how these fusions impact the response to EGFR TKIs in vitro.
